Aimee C Talleur

List of Publications by Year
in descending order

42 papers	494 citations	840776 11 h-index	752698 20 g-index
44 all docs	44 docs citations	44 times ranked	554 citing authors

#	Article	IF	Citations
1	Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Therapy, 2023, 30, 222-231.	4.5	4
2	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Transplantation and Cellular Therapy, 2022, 28, 73.e1-73.e9.	1.2	20
3	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, 262.e1-262.e10.	1.2	1
4	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. Frontiers in Oncology, 2022, 12, 845540.	2.8	10
5	Venetoclax-Based Combination Therapy As a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Children with Relapsed/Refractory AML. Transplantation and Cellular Therapy, 2022, 28, S120-S121.	1.2	1
6	Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Advances, 2022, 6, 3398-3403.	5.2	17
7	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	5.2	20
8	Bone mineral density (BMD) deficits in adult survivors of childhood cancer: Attributable risks and long-term consequences.. Journal of Clinical Oncology, 2022, 40, e22021-e22021.	1.6	0
9	Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discovery, 2022, 12, 2098-2119.	9.4	24
10	Chimeric Antigen Receptor T-cell Therapy. Hematology/Oncology Clinics of North America, 2022, 36, 701-727.	2.2	6
11	Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transplantation, 2021, 56, 1866-1875.	2.4	7
12	Infectious Outcomes in Pediatric Patients Undergoing CD19-CAR T Cell Therapy â€“ a Single Center Experience. Transplantation and Cellular Therapy, 2021, 27, S211.	1.2	0
13	Hemophagocytic lymphohistiocytosisâ€like toxicity (carHLH) after CD19â€specific CAR Tâ€cell therapy. British Journal of Haematology, 2021, 194, 701-707.	2.5	61
14	Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient with erythropoietic protoporphyria. Pediatric Transplantation, 2021, 25, e13966.	1.0	2
15	CD19-CAR TÂcells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Reports, 2021, 37, 110079.	6.4	48
16	CD45RA-Depleted Haploidentical Transplantation Combined with NK Cell Addback Results in Promising Long-Term Outcomes in Pediatric Patients with High-Risk Hematologic Malignancies. Blood, 2021, 138, 172-172.	1.4	3
17	CD19-CAR T Cells Develop Exhaustion Epigenetic Programs during a Clinical Response. Blood, 2021, 138, 2782-2782.	1.4	0
18	CD45RO+ T-Cell Add Back and Prophylactic Blinatumomab Administration Post TcrÎ±Î²/CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia. Blood, 2021, 138, 2897-2897.	1.4	2

#	Article	IF	Citations
19	152â€...Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages. , 2021, 9, A160-A161.		0
20	Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey. Frontiers in Oncology, 2021, 11, 798236.	2.8	7
21	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplantation, 2020, 55, 929-938.	2.4	31
22	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. , 2020, 8, e001563.		22
23	Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. , 2020, 8, e000176.		14
24	Second Allogeneic Hematopoietic Cell Transplant Is a Successful Salvage Modality for Pediatric Patients Who Relapse after First Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, S85-S86.	2.0	0
25	Haploidentical CD45RA-Negative Donor Lymphocyte Infusions Are Feasible, Safe and Associated with Clinical Benefit. Biology of Blood and Marrow Transplantation, 2020, 26, S268.	2.0	3
26	Autologous Hematopoietic Cell Transplantation without Transfusion in a Teenage Jehovah's Witness: A Case Report from a Pediatric Transplant Center. Biology of Blood and Marrow Transplantation, 2020, 26, S137.	2.0	0
27	Thoughts from the threshold: patient and family hopes, fears, values, and goals at the onset of pediatric hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 1103-1113.	2.4	13
28	Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience. Bone Marrow Transplantation, 2020, 55, 1357-1366.	2.4	6
29	Allogeneic CAR Cell Therapyâ€"More Than a Pipe Dream. Frontiers in Immunology, 2020, 11, 618427.	4.8	64
30	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
31	Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?. Hematology American Society of Hematology Education Program, 2020, 2020, 508-511.	2.5	4
32	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. International Journal for Quality in Health Care, 2019, 31, 633-638.	1.8	3
33	Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27964.	1.5	3
34	Autologous CD19-CAR T-Cells for the Treatment of Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients: An initial Report from an Institutional Phase I/II Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S265.	0.4	1
35	Allogeneic<scp>CD</scp>27â€depleted cells in adoptive cell therapy. Advances in Cell and Gene Therapy, 2019, 2, e45.	0.9	1
36	Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. Radiotherapy and Oncology, 2019, 134, 89-95.	0.6	2

#	Article	IF	Citations
37	Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplantation, 2018, 53, 84-90.	2.4	26
38	Sequential Infusion of TcrÎ±Î²- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies. Blood, 2018, 132, 4574-4574.	1.4	0
39	Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colonyâ€“Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2017, 23, 1910-1917.	2.0	35
40	1184 PAGING ACTIVITY AND SLEEP DISRUPTIONS FOR MEDICAL RESIDENTS DURING OVERNIGHT SHIFTS. Sleep, 2017, 40, A442-A442.	1.1	0
41	Limited Margin Radiation Therapy for Children and Young Adults With Ewing Sarcoma Achieves High Rates of Local Tumor Control. International Journal of Radiation Oncology Biology Physics, 2016, 96, 119-126.	0.8	28
42	Chimeric antigen receptor engineered allogeneic CD27-negative T cells for the treatment of CD19+ leukemia.. Journal of Clinical Oncology, 2016, 34, 3046-3046.	1.6	0